The Venture Codex Logo

The Venture Codex

GSK

2929 Walnut Street, Suite 1700, Philadelphia, PA, 19104, United States

Overview

Science-led global healthcare company developing innovative medicines.

Founded

2000

Deals ยท 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series A

Geographic focus

Switzerland
United Kingdom
United States

Sector focus

Consumer
Health Care
Pharmaceutical
Venture Capital

Investment portfolio

7rounds
NAMEDATESIZE
Ouro Medicines
Jan 2025Participated
$120 MSeries A
Elegen
May 2024Participated
$35 MSeries B
BioVersys
May 2024Led
$14 MSeries C
Sitryx Therapeutics
Sep 2023Participated
$39 MOther Equity
SpringWorks Therapeutics
Sep 2022Led
$75 MOther Equity
Sitryx Therapeutics
Oct 2018Participated
$30 MSeries A
23andMe
Jul 2018Led
$300 MOther Equity
Ouro Medicines
Jan 2025Participated
$120 MSeries A
Elegen
May 2024Participated
$35 MSeries B
BioVersys
May 2024Led
$14 MSeries C
Sitryx Therapeutics
Sep 2023Participated
$39 MOther Equity
SpringWorks Therapeutics
Sep 2022Led
$75 MOther Equity
Sitryx Therapeutics
Oct 2018Participated
$30 MSeries A
23andMe
Jul 2018Led
$300 MOther Equity
7
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

GSK: 7 funding rounds are recorded in the selected participation categories.All available history.
GSK: 7 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A02
Series B01
Series C+10
Other Equity21

Monthly Deal Activity

GSK: 7 deals are recorded across 100 months.All available history.
GSK: 7 deals are recorded across 100 months. All available history
MonthDeals
Jul '181
Aug '180
Sep '180
Oct '181
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '190
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '221
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '231
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '242
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '251
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

GSK: Health & Life Sciences is the largest displayed sector by deal count (7 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

GSK: Health & Life Sciences is the largest displayed sector by deal count (7 deals). All available history
SectorDeals
Health & Life Sciences7

Deal Size Distribution

GSK: 7 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

GSK: 7 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M1
$25M-$50M3
$50M-$100M1
$100M-$250M1
$250M-$500M1
$500M-$1B0
$1B+0

Deals By Geography

GSK: United States has the largest recorded deal count among the displayed regions (4 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

GSK: United States has the largest recorded deal count among the displayed regions (4 deals). All available history
RegionDeals
United States4
Europe3
GSK: 20 co-investors are shown, with Longwood Fund sharing 2 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

GSK: 20 co-investors are shown, with Longwood Fund sharing 2 recorded deals. All available history
Co-investorShared deals
Longwood Fund2
Sofinnova Partners2
SV Health Investors2
8VC1
ACVC Partners1
Agilent Technologies1
Alix Ventures1
AME Cloud Ventures1
Andreessen Horowitz1
Digitalis Ventures1
Eli Lilly and Company1
KdT Ventures1
LongRiver Investments1
Monograph Capital1
New Enterprise Associates1
Norwest Venture Partners1
Oxford Science Enterprises1
TPG Life Sciences Innovation1
Triatomic Capital1
UPMC Enterprises1

Investment Strategy

GSK: Led accounts for 43% and participating for 57% of round participation.All available history.
GSK: Led accounts for 43% and participating for 57% of round participation. All available history
CategoryDeals (count)Share (%)
Led343%
Participating457%
GSK: Single-lead accounts for 100% and co-led for 0% of lead dynamics.All available history.
GSK: Single-lead accounts for 100% and co-led for 0% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead3100%
Co-led00%

Team

Emma Walmsley

CEO

Gregory Reinaud

VP R&D Strategy

Jerome Andries

SVP finance R&D

Jim Kennedy

Product Manager / Tribe Leader NGS Vaccines

Mehdi El Gueddari

Principal Software Engineer

Philip Thomson

Senior Operational Technology Security Manager

Radu Rapiteanu

Scientific Leader, Functional Genomics

Satish Maram

Global Director ECommerce